Skip to content
DataLookout
Menu

NCT05669664

Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers

StatusActive, Not Recruiting
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 68 versions: 36 with changes below, 14 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria shortened, about 10 words Show 5 more changesShow less
    • Study completion pushed from Nov 30, 2026 to Nov 12, 2027
    • Enrollment target: estimated 21 to confirmed 20
    • Primary completion date changed from estimate of Nov 30, 2026 to Nov 12, 2026
    • Secondary endpoints: details revised at 2 of 3 entries
    • Site details revised at 3 of 27 sites
  2. Minor Study sites revised (27)v67
  3. Minor Study sites revised (27)v66
  4. Minor Primary and study completion moved earlier from Apr 11, 2027 to Nov 30, 2026v65
  5. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 27 of 27 sites
    v62
Show 31 earlier versionsHide 31 earlier versions
  1. Minor Site details revised at 2 of 27 sitesv61
  2. Minor Site details revised at 2 of 27 sitesv60
  3. Study Identification, Study Statusv58
  4. Minor Site details revised at 1 of 27 sitesv55
  5. Minor Study sites: 26 to 27v54
  6. Minor Site details revised at 1 of 26 sitesv52
  7. Minor Interventions: Biopsy (Procedure), Biospecimen Collection (Procedure), Computed Tomography (Procedure), Darolutamide (Drug), Leuprolide Acetate (Drug)… to Biopsy Procedure (Procedure), Biospecimen Collection (Procedure), Computed Tomography (Procedure), Darolutamide (Drug), Leuprolide Acetate…v51
  8. Minor Study sites: 25 to 26v50
  9. Minor Study sites: 22 to 25v49
  10. Minor Enrollment target: 20 to 21v47
  11. Minor Site details revised at 1 of 22 sitesv45
  12. Minor Site details revised at 1 of 22 sitesv44
  13. Minor Site details revised at 1 of 22 sitesv43
  14. Minor Study sites: 21 to 22v42
  15. Minor Site details revised at 1 of 21 sitesv41
  16. Minor Study sites: 20 to 21v40
  17. Minor Site details revised at 1 of 20 sitesv39
  18. Minor Site details revised at 1 of 20 sitesv38
  19. Minor Study sites: 19 to 20v36
  20. Minor Site details revised at 1 of 19 sitesv34
  21. Minor Site contacts updated at 1 of 19 sitesv33
  22. Minor Site details revised at 1 of 19 sitesv32
  23. Minor Study sites revised (19)v31
  24. Minor Site contacts updated at 1 of 19 sitesv30
  25. Minor Study sites: 18 to 19v26
  26. Minor Study sites: 17 to 18v25
  27. Minor Study sites: 16 to 17v24
  28. Minor Study sites: 15 to 16v23
  29. Minor Study sites revised (15)v22
  30. Minor Start date changed from estimate of Jan 9, 2024 to Jul 20, 2023v20
  31. Minor Study sites: 14 to 15v19
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Best overall response (BOR)
Timeframe: Within 1 year of initiating treatment

Secondary (3)

Progression-free survival (PFS)
Overall survival (OS)
Incidence of adverse events (AEs)

Arms and interventions

Treatment (darolutamide, leuprolide acetate)Experimental

Patients receive darolutamide PO BID on days 1-28 of each cycle and leuprolide acetate IM every 4 or 12 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy, collection of blood samples, and CT/MRI throughout the trial.

Procedures: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging

Drugs: Darolutamide, Leuprolide Acetate

Sites

27 sites in 1 country